GeoVax study suggests Ebola vaccine could provide 100% protection with single dose

GeoVax Labs (OTCQB:GOVX) published research showing that a single intramuscular dose of its Ebola vaccine, GEO-EM01, provided 100% protection in rhesus macaques challenged with a lethal dose of Ebola virus.

GEO-EM01 uses GeoVax’s Modified Vaccinia Ankara (MVA) virus-like particle platform, which generates a cell- and antibody-mediated immune response. According to GeoVax, this is the first time a single-dose vaccination using an MVA vector has conferred full protection against a lethal Ebola virus challenge in macaques.

The article, published in the open-access journal Atlas of Science, can be viewed here. Results of the study were originally published in the peer-reviewed, open access journal Scientific Reports by Nature Research and can be viewed here.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.